Economic evaluation of orthopedic and surgical interventions in hemophiliacs - Not only direct medical costs matter

36th Hemophilia Symposium Hamburg 2005

Volumn , Issue , 2007, Pages 161-167

  Mihailov, D ^a   Serban, M ^a   Badeti, R ^a   Tepeneu, P ^a   Schramm, W ^b   Lighezan, D ^a  

^a Abt Hämostaseologie ^*

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892320557     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-36715-4_30     Document Type: Chapter

References (8)

1. Evans C, Crawford B. Patient self-reports in pharmacoeconomic studies. Their use and impact on study validity. Pharmacoeconomics 1999; 15(3):241-156
2. McLoughlin V, Leatherman S. Quality or financing: what drives design of the health care system? Qual Saf Health Care 2003; 12:136-142
3. Robertson J, Lang D, Hill S. Use of pharmacoeconomics in prescribing research. Part 1: Costs-moving beyond the acquisition price for drugs. J Clin Pharm Ther 2003; 28(1):73-79
4. Schramm W, Szucs TD. State-of-the-art principles and practices of medical economics. Haemophilia 1998; 4:491-497
5. Szucs TD, Offner A, Schramm W. Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia 1996; 2:211-217
6. Schramm W. Towards the Best Use of Safe Clotting Factor Concentrates.Hämostaseologie 1996; 16:269-273
7. Wilkinson RG. Socioeconomic determinants of health: Health inequalities: relative or absolute material standards?. BMJ 1997; 314:591
8. Xu K, Evans DB, Kawabata K, et al. Household catastrophic health expenditure: a multicoutry analysis. Lancet 2003; 362:111-117